All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-04-29T14:50:35.000Z

FDA grants Annamycin Fast Track Designation for relapsed or refractory AML

Apr 29, 2019
Share:

Bookmark this article

Annamycin, a next-generation liposome formulated anthracycline, was granted Fast Track Designation by the FDA on 18 April 2019. The drug will be used for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).

According to the manufacturers, Moleculin Biotech, the drug has little to no cardiotoxicity, and avoids multidrug resistance. In patients where standard of care has failed, Annamycin has shown activity.

Efficacy of the drug has been tested in phase I and II trials, resulting in little to no reported cardiotoxicity, with the therapy even clearing patients’ leukemic blasts to a level sufficient for bone marrow transplant.1

The drug has demonstrated clinical activity in a patient population for whom there is currently no effective therapy, and since it can avoid multi-drug resistance, it will not go on to limit the effectiveness of currently approved anthracyclines.

Two separate phase I/II trials are being conducted using patients with relapsed or refractory AML, in Poland (NCT03388749) and in the US (NCT03315039). Results of these trials could determine whether Annamycin receives accelerated approval, and assuming that similar results to previous trials are achieved, this would seem likely.

  1. Wetzler, M. et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun 10.13(4):430-434. DOI: 1016/j.clml.2013.03.015
More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox